PARC Clinical Research
Adelaide, Western Australia, Australia
NCT Number: NCT05752526
The goal of this clinical trial is to compare 1% and 3% diclofenac gel (DARE-PDM1) to placebo in women with symptomatic primary dysmenorrhea. The main question it aims to answer are:
Is DARE-PDM1 1%, 3% diclofenac gel systemically safe? What are the systemic levels of DARE-PDM1 1%, 3% diclofenac gel in plasma and vaginal fluid following 1 dose and 3 doses.
Participants will be seen for routine safety evaluations and complete a daily diary recording dysmenorrhea associated pain.
Looking for future studies?
Notify Me18 year–50 year
Female
Interventional
Phase 1
Adelaide, Western Australia, Australia
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
vaginal hydrogel containing 1% Diclofenac
vaginal hydrogel containing 3% Diclofenac
vaginal hydrogel, no active ingredient
Time frame: 7 days
Evaluate the plasma pharmacokinetics of diclofenac after a single dose of DARE-PDM1
Time frame: 3 days
Evaluate the plasma pharmacokinetics of diclofenac after three doses of DARE-PDM1
Time frame: 3 days
Evaluate the vaginal fluid pharmacokinetics of diclofenac after three doses of DARE-PDM1
Time frame: 7 days
Evaluate the vaginal fluid pharmacokinetics of diclofenac after a single dose of DARE-PDM1
Time frame: 60 days
Compare genital safety of DARE-PDM1 versus placebo through vaginal exams
Time frame: 60 days
Evaluate systemic safety of DARE-PDM1 versus placebo through safety laboratory assessments
Time frame: 60 days
Evaluate the efficacy of DARE-PDM1 versus placebo in reducing dysmenorrhea associated pain
Time frame: 60 days
Evaluate the number of pain medication doses needed while using DARE-PDM1
Daré Bioscience, Inc.
Industry
A Phase 1, Multi-site, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Pharmacokinetics, Safety and Preliminary Efficacy of Two Strengths of DARE-PDM1 (1% or 3%) Versus Placebo Among Women With Symptomatic Primary Dysmenorrhea
Acronym: DARE-PDM1
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07590232
Dysmenorrhea Primary, Neurologic Manifestations
Erzurum, Turkey (Türkiye)
View Trial DetailsNCT07466342
Dysmenorrhea Primary, Mefenamic Acid
Multan, Punjab Province, Pakistan
View Trial DetailsNCT06750393
Behavior, Dysmenorrhea
Sialkot, Pjunjab, Pakistan
View Trial DetailsNCT06738212
Behavior, Dysmenorrhea Primary
Lahore, Punjab Province, Pakistan
View Trial Details